3-[3-bromo-4-hydroxy-5-(3-phenyl-propionyl)-phenyl]-propionic acid | 277313-04-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 3-[3-bromo-4-hydroxy-5-(3-phenyl-propionyl)-phenyl]-propionic acid
• 英文别名: 3-[3-bromo-4-hydroxy-5-(3-phenylpropanoyl)phenyl]propanoic acid
• CAS: 277313-04-9
• 化学式: C₁₈H₁₇BrO₄
• 分子量: 377.235
• InChiKey: BZCSUNVGFTWRPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[3-bromo-4-hydroxy-5-(3-phenyl-propionyl)-phenyl]-propionic acid 在 三乙胺 作用下， 以 甲醇 为溶剂， 生成 3-[3-(3-benzyl-5-carbamimidoyl-1H-indol-2-yl)-5-bromo-4-hydroxy-phenyl]-propionic acid
  参考文献：
  名称：

  Development of potent and selective factor Xa inhibitors

  摘要：

  The development of potent and selective small molecule inhibitors of factor Xa is described. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00311-0
• 作为产物：
  描述：

  3-[4-hydroxy-3-(3-phenyl-propionyl)-phenyl]-propionic acid 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 2.5h， 生成 3-[3-bromo-4-hydroxy-5-(3-phenyl-propionyl)-phenyl]-propionic acid
  参考文献：
  名称：

  (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors

  摘要：

  本发明提供了Formula (I)的新化合物：A-B，其前药形式，或其药学上可接受的盐，其中A代表饱和、不饱和或部分不饱和的双环杂环环结构，B代表芳基或杂芳基团。本发明的首选化合物包括苯并咪唑或吲哚核。本发明的化合物是丝氨酸蛋白酶、尿激酶（uPA）、Xa因子（FXa）和/或VIIa因子（FVIIa）的抑制剂，并具有作为抗癌剂和/或抗凝血剂的用途，用于治疗或预防哺乳动物的血栓栓塞疾病。

  公开号：

  US06867200B1

文献信息

• (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
  申请人：Allen Darin A.

  公开号：US06867200B1

  公开（公告）日：2005-03-15

  The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.

  本发明提供了Formula (I)的新化合物：A-B，其前药形式，或其药学上可接受的盐，其中A代表饱和、不饱和或部分不饱和的双环杂环环结构，B代表芳基或杂芳基团。本发明的首选化合物包括苯并咪唑或吲哚核。本发明的化合物是丝氨酸蛋白酶、尿激酶（uPA）、Xa因子（FXa）和/或VIIa因子（FVIIa）的抑制剂，并具有作为抗癌剂和/或抗凝血剂的用途，用于治疗或预防哺乳动物的血栓栓塞疾病。
• (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP1140859A2

  公开（公告）日：2001-10-10
• US6867200B1
  申请人：——

  公开号：US6867200B1

  公开（公告）日：2005-03-15
• [EN] PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTEASES
  申请人：AXYS PHARM INC

  公开号：WO2000035886A2

  公开（公告）日：2000-06-22

  The present invention provides novel compounds of the Formula (I): A-B, its prodrug forms, or pharmaceutically acceptable salts thereof, wherein A represents a saturated, unsaturated, or a partially unsaturated bicyclic heterocyclic ring structure, and B represents an aryl or a heteroaryl group. Preferred compounds of the present invention comprise a benzimidazole or indole nucleus. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.
• Development of potent and selective factor Xa inhibitors
  作者：Roopa Rai、Aleksandr Kolesnikov、Yong Li、Wendy B Young、Ellen Leahy、Paul A Sprengeler、Erik Verner、William D Shrader、Jana Burgess-Henry、Joan C Sangalang、Darin Allen、Xi Chen、Bradley A Katz、Christine Luong、Kyle Elrod、Lynne Cregar

  DOI：10.1016/s0960-894x(01)00311-0

  日期：2001.7

  The development of potent and selective small molecule inhibitors of factor Xa is described. (C) 2001 Elsevier Science Ltd. All rights reserved.